Surgical delivery of drug releasing poly(lactic-co-glycolic acid)/poly(ethylene glycol) paste with in vivo effects against glioblastoma.
暂无分享,去创建一个
K. Shakesheff | C. Rahman | Toby Gould | Stuart Smith | Philip A. Clarke | Alison Ritchie | Jennifer H. Ward | Richard Grundy | Ruman Rahman
[1] K. Shakesheff,et al. Controlled release of BMP‐2 from a sintered polymer scaffold enhances bone repair in a mouse calvarial defect model , 2014, Journal of tissue engineering and regenerative medicine.
[2] K. Shakesheff,et al. Adjuvant Chemotherapy for Brain Tumors Delivered via a Novel Intra-Cavity Moldable Polymer Matrix , 2013, PloS one.
[3] Giles T S Kirby,et al. PLGA/PEG-hydrogel composite scaffolds with controllable mechanical properties. , 2013, Journal of biomedical materials research. Part B, Applied biomaterials.
[4] G. Barnett,et al. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions , 2012, Expert opinion on investigational drugs.
[5] T. Golub,et al. Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion , 2012, Nature.
[6] J. Lowe,et al. CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma , 2012, Acta Neuropathologica.
[7] Y. Reinwald,et al. Analysis of sintered polymer scaffolds using concomitant synchrotron computed tomography and in situ mechanical testing , 2011, Journal of materials science. Materials in medicine.
[8] J. Rich,et al. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. , 2011, Cell stem cell.
[9] R. Bristow,et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. , 2010, Cancer research.
[10] Ruman Rahman,et al. Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma , 2010, Journal of oncology.
[11] M. Wolter,et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. , 2010, Brain : a journal of neurology.
[12] R. McLendon,et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype , 2009, Cell cycle.
[13] N. Laperriere,et al. Gliadel wafers in the treatment of malignant glioma: a systematic review , 2007, Current oncology.
[14] A. Péna,et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. , 2006, AJNR. American journal of neuroradiology.
[15] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[16] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[17] Z. Ram,et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.
[18] P. Brennan,et al. Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[20] I. Cuthill,et al. Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .
[21] I. Bayazitov,et al. A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.
[22] W. Saltzman,et al. Pharmacokinetics of the Carmustine Implant , 2002, Clinical pharmacokinetics.